Prelude to pancuronium and vecuronium

Anaesthesia

Volumn 55, Issue 6, 2000, Pages 551-556

  McKenzie, A G ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

History: pancuronium; vecuronium; Neuromuscular relaxants: pancuronium; vecuronium

Indexed keywords

AMMONIA; GALLAMINE; MALOUETINE; NEUROMUSCULAR BLOCKING AGENT; PANCURONIUM BROMIDE; TUBOCURARINE CHLORIDE; UNCLASSIFIED DRUG; VECURONIUM;

CORONARY ARTERY DISEASE; DIPYRANDIUM; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HEART VALVE REPLACEMENT; HUMAN; NONHUMAN; REVIEW; TACHYCARDIA;

HISTORY, 20TH CENTURY; HUMANS; NEUROMUSCULAR NONDEPOLARIZING AGENTS; NICOTINIC ANTAGONISTS; PANCURONIUM; PLANT EXTRACTS; VECURONIUM BROMIDE;

EID: 0034076965     PISSN: 00032409     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2044.2000.01423.x     Document Type: Review

References (38)

1. Brown DL, Brock-Utne JG. The first structure-function approach to drug design in anaesthesia. Anaesthesia 1997; 52: 1202-4.
2. Paez R. Wild Scenes in South America or Life in the Llanos of Venezuela. New York: Charles Scribner, 1868: 206-8.
3. Woodson RE Jr. Studies in the Apocynaceae IV The American Genera of Echitoideae: VIII Malouetia. Annals of Missouri Botanical Gardens 1935; 22: 238-70.
4. Woodson RE Jr. Studies in the Apocynaceae VI. Philippine Journal of Science 1936; 60: 205-32.
5. Pichon M. Classification des Apocynacées: XXXIV, les Malouetiinae D'Afrique. Bulletin Du Jardin Botanique de L'Etat, Bruxelles 1952; 22: 115-35.
6. Churchill-Davidson HC. The muscle relaxants. British Medical Bulletin 1958; 14: 31-3.
7. Bovet D. Some aspects of the relationship between chemical constitution and curare-like activity. Annals of the New York Academy of Sciences 1951; 54: 407-37.
8. Crum-Brown A, Fraser TR. On the Connection between Chemical Constitution and Physiological Action. Part I. On the Physiological Action of the Salts of the Ammonium Bases, derived from Strychnine, Brucia, Thebaia, Codeia, Morphia, and Nicoria. Part II. On the Physiological Action of the Ammonium Bases derived from Atropia and Conia. Transactions of Royal Society of Edinburgh 1869; 25: 151-203;693-739.
9. Burn JH. The action of conessine and holarrhenine, the alkaloids of Holarrhena congolensis, and also of oxyconessine. Journal of Pharmacology and Experimental Therapeutics 1915; 6: 305-21.
10. Stephenson RP. The pharmacological properties of conessine, isoconessine and neoconessine. British Journal of Pharmacology and Chemotherapy 1948; 3: 237-45.
11. Janot M-M, Lainé F, Goutarel R. Alcaloïdes stéroides V. Alcaloïdes du Malouetia bequaertiana E. Woodson (Apocynacées): La funtuphyllamine B et la malouétine. Annales Pharmaceutiques Françaises 1960; 18: 673-7.
12. Quevauviller A, Lainé F. Sur la toxicité et la pouvoir curarisant du chlorure de malouétine. Annales Pharmaceutiques Françaises 1960; 18: 678-80.
13. 1. Annales Pharmaceutiques Françaises 1965; 23: 395-409.
14. Alauddin M. Synthetic approaches to steroidal bisquaternary ammonium compounds. PhD Thesis. University of Glasgow, 1962.
15. Alauddin M, Martin-Smith M. Biological activity in steroids possessing nitrogen atoms. Part I. Synthetic Nitrogenous Steroids. Journal of Pharmacy and Pharmacology 1962; 14: 325-49.
16. Alauddin M, Caddy B, Lewis JJ, Martin-Smith M, Sugrue MF. Non-depolarising neuromuscular blockade by 3α, 17α-bis (quaternary ammonium) 5α-androstanes. Journal of Pharmacy and Pharmacology 1965; 17: 55-8.
17. Paton WDM, Zaimis EJ. The pharmacological actions of polymethylene bistrimethylammonium salts. British Journal of Pharmacology 1949; 4: 381-400.
18. Loewe S, Harvey SC. Equidistance concept and structure-activity relationship of curarizing drugs. Naunyn-Schmiedeberg's Archiv für Experimentelle Pathologie und Pharmakologie 1952; 214: 214-26.
19. Martin-Smith M. Rational Elements in the Development of Superior Neuromuscular Blocking Agents. In: Ariens EJ, ed. Drug Design, Vol. II. New York: Academic Press, 1971; 453-530.
20. Bowman WC. The discovery & evolution of aminosteroidal neuromuscular blocking agents. In: Denissen P, ed. The Development of Aminosteroidal Neuromuscular Blocking Agents. Interface Symposium (10th World Congress of Anaesthesiologists), The Hague, 1992: pp. 3-20.
21. Biggs RS, Davis M, Wien R. Muscle-relaxant Properties of a Steroid bis-Quaternary Ammonium Salt. Experientia 1964; 20: 119-20.
22. Mushin WW, Mapleson WW. Relaxant action in man of dipyrandium chloride (M & B 9105A). British Journal of Anaesthesia 1964; 36: 761-8.
23. Busfield D, Child KJ, Clarke AJ, Davis B, Dodds MG. Neuromuscular blocking activities of some steroidal mono and bis-quaternary ammonium compounds with special reference to NN′-dimethylconessine. British Journal of Pharmacology & Chemotherapy 1968; 33: 609-23.
24. Khuong-Huu-Lainé F, Pinto-Scognamiglio W. Activité curarisante du dichlorure de 3β, 20α - bistrimethylammonium 5α - pregnane (malouétine) et de ses stéreoisomères. Archives Internationales de Pharmacodynamie et de Thérapie 1964; 147: 209-19.
25. Bamford DG, Biggs DF, Davis M, Parnell EW. Neuromuscular blocking properties of stereoisomeric androstane-3, 17-bisquaternary ammonium salts. British Journal of Pharmacology & Chemotherapy 1967; 30: 194-202.
26. Buckett WR. Steroidal Neuromuscular Blocking Agents. In: Harper NJ, Simmonds AB, eds. Advances in Drug Research 10. New York: Academic Press, 1975: 53-92.
27. Baird WLM, Reid AM. The neuromuscular blocking properties of a new steroid compound, pancuronium bromide - a pilot study in man. British Journal of Anaesthesia 1967; 39: 775-80.
28. Buckett WR, Bonta IL. Pharmacological studies with NA97 (2β, 16β-dipiperidino-5α- androstane-3α, 17β-diol diacetate dimethobromide). Federation Proceedings 1966; 25: 718.
29. Buckett WR, Marjoribanks CEB, Marwick FA, Morton MB. The pharmacology of pancuronium bromide (Org NA 97) a new steroidal neuromuscular blocking agent. British Journal of Pharmacology & Chemotherapy 1968; 32: 671-82.
30. Baird WLM, Buckett WR. The pharmacology of pancuronium bromide - a new neuromuscular blocking agent. In: Boulton TB, et al. eds. Proceedings of 4th World Congress of Anaesthesiologists. Amsterdam: Excerpta Medica Foundation, 1970; 1275.
31. Buckett WR, Hewett CL, Savage DS. Pancuronium bromide and other steroidal neuromuscular blocking agents containing acetylcholine fragments. Journal of Medicinal Chemistry 1973; 16: 1116-24.
32. Crul JF, Booij LHDJ. First clinical experiences with ORG NC 45. British Journal of Anaesthesia 1980; 52: 49S-52S.
33. Saxena PR, Bonta IL. Mechanism of selective cardiac vagolytic action of pancuronium bromide. Specific blockade of cardiac muscarinic receptors. European Journal of Pharmacology 1970; 11: 332-41.
34. Hughes R, Chapple DJ. Effects of non-depolarizing neuromuscular blocking agents on peripheral autonomic mechanisms in cats. British Journal of Anaesthesia 1976; 48: 59-67.
35. Durant NN, Marshall IG, Savage DS, Nelson DJ, Sleigh T, Carlyle IC. The neuromuscular and autonomie blocking activities of pancuronium, Org NC 45, and other pancuronium analogues, in the cat. Journal of Pharmacy and Pharmacology 1979; 31: 831-6.
36. Marshall IG, Agoston S, Booij LHDJ, Durant NN, Foldes FF. Pharmacology of ORG NC 45 compared with other non-depolarizing neuromuscular blocking drugs. British Journal of Anaesthesia 1980; 52: 11S-19S.
37. Agoston S, Salt P, Newton D, Bencini A, Boomsma P, Erdmann W. The neuromuscular blocking action of ORG NC 45, a new pancuronium derivative, in anaesthetized patients - a pilot study. British Journal of Anaesthesia 1980; 52: 53S-59S.
38. Savage DS, Sleigh T, Carlyle I. The emergence of ORG NC 45, 1-[(2β, 3α, 16β, 17β)-3, 17-bis (acetyloxy)-2-(1-piperidinyl)-androstan-16-yl]-1-methylpiperidinium bromide, from the pancuronium series. British Journal of Anaesthesia 1980; 52: 3S-9S.